CN Patent

CN101360723A — 制备嘧啶二酮衍生物的方法

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2009-02-04 · 17y expired

What this patent protects

制备式(I)化合物的方法，其中变量如说明书中所定义。另外，制备可用于抑制二肽基肽酶的化合物的方法。

USPTO Abstract

制备式(I)化合物的方法，其中变量如说明书中所定义。另外，制备可用于抑制二肽基肽酶的化合物的方法。

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: CN101360723A
Jurisdiction: CN
Classification: —
Expires: 2009-02-04
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.